EMPERIAL-heart-failure-toplineresults
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Empagliflozin | Heart | Heart Failure | Jardiance | Research | Sports Medicine | Study